Search

Ninerafaxstat

Ninerafaxstat is under investigation in clinical trial NCT07023614 (A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

MF-300

As a potential candidate for the treatment of sarcopenia, it has undergone phase 1 studies to evaluate safety, tolerability, and PK/PD characteristics.[A275368,L54983]

AT9283

AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer.

Diphemanil

Bisegliptin

It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion

Onapristone

treatment of Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Androgen-independent Prostate Cancer, and Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no

Puromycin

Puromycin is toxic to both prokaryotic and eukaryotic cells, resulting in significant cell death at appropriate doses.

Eptazocine

The usage of the INN stem '-azocine' in the name indicates that Eptazocine is a narcotic antagonist/agonist related to 6,7-benzomorphan. Eptazocine has a monoisotopic molecular weight of 231.16 Da.

Difloxacin

However, it presents a reduced efficacy when compared to other fluoroquinolone antibacterials.

Ketazocine

The usage of the INN stem '-azocine' in the name indicates that Ketazocine is a narcotic antagonist/agonist related to 6,7-benzomorphan. Ketazocine has a monoisotopic molecular weight of 285.17 Da.